Inventors:
Nader Najafian - Brookline MA, US
Mohamed H. Sayegh - Westwood MA, US
Melanie Ruzek - Danielson CT, US
Srinivas Shankara - Shrewsbury MA, US
John Williams - Hopkinton MA, US
Johanne Kaplan - Sherborn MA, US
John M. McPherson - Hopkinton MA, US
International Classification:
A61K 35/18, A61K 38/17, A61P 37/00, C12N 5/0783
Abstract:
Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.